None listed
Conditions
Interventions
None listed
Sponsors
Daiichi-Sankyo Korea
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males or females aged = 65 years with a diagnosis of dyslipidemia 2. Patients who were prescribed Mevalotin® in the judgment of their physicians, or who started receiving Mevalotin® tab. within 6 weeks from enrollment in this observational study 3. Voluntary written consent to participation in this observational study by the patients or their representatives
Exclusion criteria
Exclusion criteria: There will be no particular exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of subjects who attain the LDL-C goal defined in the 2015 Korean Guidelines for Management of Dyslipidemia after the administration of Mevalotin® tab. for 24 weeks in elderly patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events and Adverse Drug Reactions;The proportion of subjects who attain the non-HDL-C goal defined in the 2015 Korean Guidelines for Management of Dyslipidemia after the administration of Mevalotin® tab. for 24 weeks in elderly patients;Percent change from baseline in the blood non-HDL-C at Week 24;Percent change from baseline in the blood LDL-C at Week 24;Percent change from baseline in the total blood cholesterol at Week 24;Percent change from baseline in the blood HDL-C at Week 24;Percent change from baseline in the blood triglycerides at Week 24 | — |
Countries
Korea, Republic of
Contacts
Public ContactWoo-yeon Lee
Seoul National University Bundang Hospital
Outcome results
None listed